762 related articles for article (PubMed ID: 25512338)
1. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Sengupta N; Feuerstein JD; Patwardhan VR; Tapper EB; Ketwaroo GA; Thaker AM; Leffler DA
Am J Gastroenterol; 2015 Feb; 110(2):328-35. PubMed ID: 25512338
[TBL] [Abstract][Full Text] [Related]
2. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding.
Witt DM; Delate T; Garcia DA; Clark NP; Hylek EM; Ageno W; Dentali F; Crowther MA
Arch Intern Med; 2012 Oct; 172(19):1484-91. PubMed ID: 22987143
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
4. Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants.
Sengupta N; Marshall AL; Jones BA; Ham S; Tapper EB
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1893-1900.e2. PubMed ID: 29775794
[TBL] [Abstract][Full Text] [Related]
5. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
6. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation.
Qureshi W; Mittal C; Patsias I; Garikapati K; Kuchipudi A; Cheema G; Elbatta M; Alirhayim Z; Khalid F
Am J Cardiol; 2014 Feb; 113(4):662-8. PubMed ID: 24355310
[TBL] [Abstract][Full Text] [Related]
7. Restarting Warfarin vs Direct Oral Anticoagulants After Major Gastrointestinal Bleeding and Associated Outcomes in Atrial Fibrillation: A Cohort Study.
Tapaskar N; Ham SA; Micic D; Sengupta N
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):381-389.e9. PubMed ID: 33227428
[TBL] [Abstract][Full Text] [Related]
8. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Chang HY; Zhou M; Tang W; Alexander GC; Singh S
BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Garcia DA; Fisher DA; Mulder H; Wruck L; De Caterina R; Halvorsen S; Granger CB; Held C; Wallentin L; Alexander JH; Lopes RD
Am Heart J; 2020 Mar; 221():1-8. PubMed ID: 31896036
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
11. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
12. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Desai J; Kolb JM; Weitz JI; Aisenberg J
Thromb Haemost; 2013 Aug; 110(2):205-12. PubMed ID: 23702623
[No Abstract] [Full Text] [Related]
15. Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy.
Kido K; Scalese MJ
Ann Pharmacother; 2017 Nov; 51(11):1000-1007. PubMed ID: 28639882
[TBL] [Abstract][Full Text] [Related]
16. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis.
Tapaskar N; Pang A; Werner DA; Sengupta N
Dig Dis Sci; 2021 Feb; 66(2):554-566. PubMed ID: 32279174
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed.
Valanejad SM; Davis KA; Nisly SA
Ann Pharmacother; 2020 Oct; 54(10):975-980. PubMed ID: 32141301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
